ZNTL Zentalis Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZNTL

Price (delayed)

$11.71

Market cap

$830.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.47

Enterprise value

$843.37M

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of ...

Highlights
The company's debt fell by 4.5% YoY
Zentalis Pharmaceuticals's EPS has increased by 3.5% from the previous quarter
Zentalis Pharmaceuticals's net income has decreased by 23% YoY and by 2.1% from the previous quarter
Zentalis Pharmaceuticals's quick ratio has decreased by 21% from the previous quarter and by 10% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zentalis.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of ZNTL
Market
Shares outstanding
70.96M
Market cap
$830.94M
Enterprise value
$843.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.9
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$292.79M
EBITDA
-$291.4M
Free cash flow
-$208.41M
Per share
EPS
-$4.47
Free cash flow per share
-$3.19
Book value per share
$6.18
Revenue per share
$0
TBVPS
$8.38
Balance sheet
Total assets
$551.69M
Total liabilities
$114.3M
Debt
$43.15M
Equity
$437.28M
Working capital
$427.35M
Liquidity
Debt to equity
0.1
Current ratio
7.16
Quick ratio
7
Net debt/EBITDA
-0.04
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-52%
Return on equity
-63.9%
Return on invested capital
-68.1%
Return on capital employed
-60.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZNTL stock price

How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
5.4%
1 week
5.88%
1 month
-25.03%
1 year
-45.1%
YTD
-22.71%
QTD
-25.7%

Financial performance

How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$299.51M
Net income
-$292.19M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 32% YoY and by 6% from the previous quarter
Zentalis Pharmaceuticals's net income has decreased by 23% YoY and by 2.1% from the previous quarter

Growth

What is Zentalis Pharmaceuticals's growth rate over time

Valuation

What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.9
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Zentalis Pharmaceuticals's EPS has increased by 3.5% from the previous quarter
The P/B is 32% less than the last 4 quarters average of 2.8
ZNTL's equity is down by 9% from the previous quarter

Efficiency

How efficient is Zentalis Pharmaceuticals business performance
ZNTL's ROIC is down by 21% year-on-year
The ROA is down by 12% year-on-year
The ROE has declined by 11% year-on-year

Dividends

What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZNTL.

Financial health

How did Zentalis Pharmaceuticals financials performed over time
Zentalis Pharmaceuticals's quick ratio has decreased by 21% from the previous quarter and by 10% YoY
The current ratio has decreased by 20% from the previous quarter and by 10% YoY
The company's debt is 90% lower than its equity
The debt to equity has grown by 11% since the previous quarter
ZNTL's equity is down by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.